Clinical Trial for Alzheimer ' s Disease - Is LMTX Ineffective or Unprecedented?

Conclusions < /u > : The outcomes of this phase 3 trial will highlight the potential therapeutic value of tau aggregation inhibitor therapy in AD. A second phase 3 trial of LMTM for AD will be completed and reported later in 2016. < br / > < br / >

Source: The Neurocritic - July 28, 2016 Category: Neuroscience Authors: The Neurocritic Source Type: blogs